LMR 7

Yves Laure Pimentel · 70問 · 2年前

通報

問題一覧

Normal values for the Addis count: ? hyaline casts in a 12-hour urine

0 to 5,000

Normal values for the Addis count: 0 to 5,000 ? in a 12-hour urine

hyaline casts

Normal values for the Addis count: 0 to 5,000 hyaline casts in a ? urine

12-hour

Centrifugation for urine microscopic exam:

400 RCF for 5 minutes

Volume of sediment, glass slide method ? covered by 22 x 22 mm coverslip

20 uL or 0.02 mL

Volume of sediment, glass slide method 20 uL or 0.02 mL covered by MM? coverslip

22 x 22 mm

More than 2 RTE cells/hpf indicates ? and specimens should be referred for cytologic urine testing CM:

tubular injury

Approximately ? of CSF is produced every hour in the choroid plexuses and reabsorbed by the arachnoid villi

20 mL

Approximately 20 mL of CSF is produced every hour in the ? and reabsorbed by the arachnoid villi

choroid plexuses

Approximately 20 mL of CSF is produced every hour in the choroid plexuses and reabsorbed by the ?

arachnoid villi

CSF Total volume in adult:

140 to 170 mL

CSF Total volume in neonate:

10 to 60 mL

Normal adult CSF ? WBCs/uL

0 to 5 WBCs/uL

. Neonates ? WBCs/uL

0 to 30

Reactive lymphocytes in CSF,

viral infections

Increased eosinophils in CSF: parasitic infections, fungal infections primarily ?

COCCIDIOIDES IMMITIS

CSF glucose is approximately ? percent that of plasma glucose

60 to 70

Normal CSF protein: ?

15 to 45 mg/dL

Normal concentration of glutamine in CSF:

8 to 18 mg/dL

SEMINAL FLUID . Liquefaction within

30 to 60 minutes

SEMINAL FLUID Volume

2 to 5 mL

SEMINAL FLUID pH

7.2 to 8

Sperm morphology: ? should be evaluated

at least 200 sperms

: at least 200 sperms should be evaluated

Sperm morphology

Sperm viability, eosin-nigrosin stain, counting number of dead cells in ? sperms

100

is evaluate in approximately 20 high-power fields

Motility

Motility is evaluate in approximately ?

20 high-power fields

Sperm concentration

20 M to 160 M per mL

Sperm count ? per ejaculate*

≥ 40 M

Most common dilution is ? prepared using a MECHANICAL (positive-displacement) rather than a Thoma pipette

1:20

Most common dilution is 1:20 prepared using a MECHANICAL (?-displacement) rather than a Thoma pipette

positive

Minimum motility of ?% with a rating of 2.0 after 1 hour is considered normal

Minimum motility of 50% with a rating of ? after 1 hour is considered normal

2.0

Fructose ? per ejaculate

≥ 13 umol

Specimens for fructose should be tested within ? to prevent fructolysis

2 hours or FROZEN

Specimens for fructose should be tested within 2 hours or FROZEN to prevent

fructolysis

RAPE, presence of sperm: (1) enhancing specimen with ? and examining under PHASE MICROSCOPY (2) ACP (3) seminal glycoprotein p30 (prostatic specific antigen [PSA]), which is present even in the absence of sperm (4) ABO, DNA

XYLENE

RAPE, presence of sperm: (1) enhancing specimen with XYLENE and examining under ? MICROSCOPY (2) ACP (3) seminal glycoprotein p30 (prostatic specific antigen [PSA]), which is present even in the absence of sperm (4) ABO, DNA

PHASE MICROSCOPY

RAPE, presence of sperm: (1) enhancing specimen with XYLENE and examining under PHASE MICROSCOPY (2) ? (3) seminal glycoprotein p30 (prostatic specific antigen [PSA]), which is present even in the absence of sperm (4) ABO, DNA

ACP

Motile sperm can be detected for up to ? after intercourse, whereas nonmotile sperm can persist for 3 days. As the sperm die off, only the heads remain and may be present for 7 days after intercourse

24 hours

Motile sperm can be detected for up to 24 hours after intercourse, whereas nonmotile sperm can persist for ?. As the sperm die off, only the heads remain and may be present for 7 days after intercourse

3 days

Motile sperm can be detected for up to 24 hours after intercourse, whereas nonmotile sperm can persist for 3 days. As the sperm die off, only the heads remain and may be present for ? after intercourse

7 days

SYNOVIAL FLUID Volume

less than 3.5 mL

SYNOVIAL FLUID Normal: COLOR

clear and pale yellow

SYNOVIAL FLUID Able to form

4 to 6 cm string

SYNOVIAL FLUID RBCs/uL

Less than 2,000 RBCs/uL

SYNOVIAL FLUID WBCs/uL

Less than 200 WBCs/uL

SYNOVIAL FLUID Glucose ? lower than the blood glucose

less than 10 mg/dL

SYNOVIAL FLUID less than 10 mg/dL lower than the blood glucose

Glucose

SEROUS FLUID: TRANSUDATES AND EXUDATES Most reliable differentiation: ? for protein and LD

Fluid-to-blood ratios

SEROUS FLUID: TRANSUDATES AND EXUDATES Most reliable differentiation: Fluid-to-blood ratios for ?

protein and LD

SEROUS FLUID: TRANSUDATES AND EXUDATES WBC counts greater than 1,000/uL and RBC counts greater than 100,000/uL are indicative of an ?

exudate

SEROUS FLUID: TRANSUDATES AND EXUDATES WBC counts ? and RBC counts greater than 100,000/uL are indicative of an

greater than 1,000/uL

SEROUS FLUID: TRANSUDATES AND EXUDATES WBC counts greater than 1,000/uL and RBC counts ? are indicative of an EXUDATES

greater than 100,000/uL

PLEURAL FLUID Pleural fluid cholesterol ?or a pleural fluid to serum cholesterol ratio greater than 0.3 provides a reliable information that the fluid is an exudate

greater than 60 mg/dL

PLEURAL FLUID Pleural fluid cholesterol greater than 60 mg/dL or a pleural fluid to serum cholesterol ratio greater than 0.3 provides a reliable information that the fluid is an ?

exudate

Fluid to serum total bilirubin ratio of ? also indicates the presence of an exudate

0.6 or more

Fluid to serum total bilirubin ratio of 0.6 or more also indicates the presence of an ?

exudate

Pleural fluid pH ? may indicate the need for chest-tube drainage, in addition to antibiotics in cases of pneumonia. The finding of pH as low as 6 indicates esophageal rupture that is allowing the influx of gastric fluid

lower than 7.3

Pleural fluid pH lower than 7.3 may indicate the need for chest-tube drainage, in addition to antibiotics in cases of pneumonia. The finding of pH as ? indicates esophageal rupture that is allowing the influx of gastric fluid

low as 6

Pleural fluid pH lower than 7.3 may indicate the need for chest-tube drainage, in addition to antibiotics in cases of pneumonia. The finding of pH as low as 6 indicates ? that is allowing the influx of gastric fluid

esophageal rupture

PERITONEAL FLUID RBC counts ? are indicative of BLUNT TRAUMA INJURIES

GREATER THAN 100,000/uL

PERITONEAL FLUID RBC counts GREATER THAN 100,000/uL are indicative of

BLUNT TRAUMA INJURIES

PERITONEAL FLUID Normal WBC counts are ?and the count increases with bacterial peritonitis and cirrhosis

less than 500 cells/uL

PERITONEAL FLUID Normal WBC counts are less than 500 cells/uL and the count increases with ? and ?

bacterial peritonitis and cirrhosis

, source is from OVARIES, FALLOPIAN TUBES or ENDOMETRIUM

CA 125 antigen

FECAL ANALYSIS Large intestine is capable of absorbing approximately ? mL of water

3,000 mL of water

FECAL ANALYSIS ? is capable of absorbing approximately 3,000 mL of water

Large intestine

FECAL ANALYSIS Most representative, for fecal fats; ? day stool collection

3-day

Muscle fibers: slide is examined for ? minutes. Only undigested fibers are counted, and the presence of more than 10 is reported as increased

Muscle fibers: slide is examined for 5 minutes. Only undigested fibers are counted, and the presence of ? is reported as increased

more than 10

: slide is examined for 5 minutes. Only undigested fibers are counted, and the presence of more than 10 is reported as increased

Muscle fibers

Bleeding in excess of ? gram of stool is considered pathologically significant

2.5 mL/150

Normal stool pH is between

7 and 8

pH below 5.5 in cases of

CARBOHYDRATE DISORDERS

pH ? in cases of CARBOHYDRATE DISORDERS

below 5.5

SCREENING PROCEDURE that is helpful in the diagnosis of many diseases, it is one indicator of the body’s ability to fight disease, it is used to MONITOR the effects of drug and radiation therapy, and it may be employed as an INDICATOR OF PATIENT’S PROGRESS in certain diseased states such as infection or anemia.

COMPLETE BLOOD COUNT

: amount of plasma that still remains in RBC portion after the microhematocrit has been spun. Increased in macrocytic anemias, spherocytosis, thalassemia, hypochromic anemia and sickle cell anemia

TRAPPED PLASMA

When comparing spun hematocrit results obtained on an electronic cell counter, the spun hematocrit results vary from ? HIGHER because of this trapped plasma (unless cell counter has been calibrated).

1 to 3%

Anticoagulated blood should be centrifuged within ? hours of collection when the blood is stored at room temperature.

: FALSELY LOW due to shrinkage of cells

Overanticoagulation

Overanticoagulation: ? due to shrinkage of cells

FALSELY LOW

denote poor technique but do not affect the results

Air bubbles

Incomplete sealing of the microhematocrit tubes:

FALSELY LOW

Inadequate centrifugation of the microhematocrit tubes or allowing the tubes to stand longer than several minutes after centrifugation:

FALSELY ELEVATED

may be expressed in either of two ways (1) as percentage, e.g., 42% or (2) as a decimal point, e.g., 0.42.

Hematocrit

WHITE BLOOD CELLS COUNT Count above 11 x 10 9th/L is termed

LEUKOCYTOSIS

WHITE BLOOD CELLS COUNT Mix the Thoma pipet for approximately ? minutes to ensure hemolysis and adequate mixing

WHITE BLOOD CELLS COUNT Mix the ? pipet for approximately 3 minutes to ensure hemolysis and adequate mixing

thoma

WHITE BLOOD CELLS COUNT Manual counts, no more than ? variation between the four squares

10-cell

WHITE BLOOD CELLS COUNT Manual counts, no more than 10-cell variation between the ?

four squares

PLATELET COUNT Prolonged BT and poor clot retraction are found when there is marked ?

thrombocytopenia

PLATELET COUNT : decreased platelet clumping but increased MPV

EDTA

PLATELET COUNT :If concentration of EDTA exceeds 2mg/mL of whole blood, platelets may ? AND THEN ?, causing invalidly higher count

SWELL and FRAGMENT

PLATELET COUNT :If concentration of EDTA exceeds 2mg/mL of whole blood, platelets may SWELL AND THEN FRAGMENT, causing invalidly ? count

higher

PLATELET COUNT :Using ? diluting fluid, the platelet count must be completed within 30 minutes of diluting in order to ensure against platelet DISINTEGRATION

Rees-Ecker

PLATELET COUNT :Using Rees-Ecker diluting fluid, the platelet count must be completed within 30 minutes of diluting in order to ensure against platelet ?

DISINTEGRATION

PLATELET COUNT :, the dilution is stable for 8 hours

1% ammonium oxalate

PLATELET COUNT :1% ammonium oxalate, the dilution is stable for ? hours

100

ERTHROCYTE SEDIMENTATION RATE tend to settle more rapidly than microcytes

Macrocytes

other names parasitology

other names parasitology

70問 • 2年前

Yves Laure Pimentel · 111問 · 2年前

PARASITOLOGY

PARASITOLOGY

111問 • 2年前

Yves Laure Pimentel · 64問 · 2年前

HTMLBE

HTMLBE

64問 • 2年前

Yves Laure Pimentel · 61問 · 2年前

CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

61問 • 2年前

Yves Laure Pimentel · 69問 · 2年前

HISTOPATHOLOGY

HISTOPATHOLOGY

69問 • 2年前

CC-2 SPECTROPHOTOMETRY

CC-2 SPECTROPHOTOMETRY

Yves Laure Pimentel · 41問 · 2年前

CC-3 ELECTROPHORESIS

CC-3 ELECTROPHORESIS

41問 • 2年前

Yves Laure Pimentel · 87問 · 2年前

AUBF LAB SAFETY

AUBF LAB SAFETY

87問 • 2年前

CSF 1

CSF 1

Yves Laure Pimentel · 82問 · 2年前

CSF 2

CSF 2

82問 • 2年前

SEMEN 1

SEMEN 1

Yves Laure Pimentel · 7問 · 2年前

SEMEN 2

SEMEN 2

7問 • 2年前

SYNOVIAL FLUID 1

SYNOVIAL FLUID 1

Yves Laure Pimentel · 6問 · 2年前

SYNOVIAL FLUID 2

SYNOVIAL FLUID 2

6問 • 2年前

Yves Laure Pimentel · 25問 · 2年前

SEROUS FLUID

SEROUS FLUID

25問 • 2年前

Yves Laure Pimentel · 44問 · 2年前

PLEURAL FLUID

PLEURAL FLUID

44問 • 2年前

Yves Laure Pimentel · 18問 · 2年前

PERICARDIAL FLUID

PERICARDIAL FLUID

18問 • 2年前

Yves Laure Pimentel · 30問 · 2年前

PERITONEAL FLUID/ ASCITIC FLUID

PERITONEAL FLUID/ ASCITIC FLUID

30問 • 2年前

Yves Laure Pimentel · 92問 · 2年前

AMNIOTIC FLUID

AMNIOTIC FLUID

92問 • 2年前

Yves Laure Pimentel · 80問 · 2年前

FECALYSIS

FECALYSIS

80問 • 2年前

Yves Laure Pimentel · 89問 · 2年前

OTHER BODY FLUIDS

OTHER BODY FLUIDS

89問 • 2年前

Yves Laure Pimentel · 86問 · 2年前

MTLBE- SUHO NOTES

MTLBE- SUHO NOTES

86問 • 2年前

Yves Laure Pimentel · 35問 · 2年前

MTLBE..

MTLBE..

35問 • 2年前

Yves Laure Pimentel · 19問 · 1年前

CC- CHROMATOGRAPHY

CC- CHROMATOGRAPHY

19問 • 1年前

Yves Laure Pimentel · 14問 · 1年前

CC-OSMOMETRY

CC-OSMOMETRY

14問 • 1年前

Yves Laure Pimentel · 43問 · 1年前

CC-ELECTROCHEMISTRY TECHNIQUES

CC-ELECTROCHEMISTRY TECHNIQUES

43問 • 1年前

Yves Laure Pimentel · 49問 · 2年前

CC- CARBOHYDRATES

CC- CARBOHYDRATES

49問 • 2年前

Yves Laure Pimentel · 97問 · 2年前

CC- DIABETES MELLITUS

CC- DIABETES MELLITUS

97問 • 2年前

Yves Laure Pimentel · 57問 · 2年前

MAJOR LIPOPROTEINS

MAJOR LIPOPROTEINS

57問 • 2年前

Yves Laure Pimentel · 63問 · 2年前

MINOR LIPOPROTEINS

MINOR LIPOPROTEINS

63問 • 2年前

Yves Laure Pimentel · 37問 · 2年前

PROTEINS

PROTEINS

37問 • 2年前

Yves Laure Pimentel · 91問 · 2年前

PLASMA PROTEINS 1

PLASMA PROTEINS 1

91問 • 2年前

Yves Laure Pimentel · 98問 · 2年前

PLASMA PROTEINS 2 (ALPHA 2 REGION)

PLASMA PROTEINS 2 (ALPHA 2 REGION)

98問 • 2年前

Yves Laure Pimentel · 61問 · 2年前

MISCELLANEOUS PROTEINS

MISCELLANEOUS PROTEINS

61問 • 2年前

Liver Function Test 1

Liver Function Test 1

Yves Laure Pimentel · 96問 · 2年前

Liver Function Test 2

Liver Function Test 2

96問 • 2年前

Yves Laure Pimentel · 33問 · 2年前

TUMOR MARKERS

TUMOR MARKERS

33問 • 2年前

Yves Laure Pimentel · 41問 · 2年前

KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

41問 • 2年前

Yves Laure Pimentel · 17問 · 2年前

GLYCOGEN STORAGE DISEASES

GLYCOGEN STORAGE DISEASES

17問 • 2年前

Yves Laure Pimentel · 14問 · 2年前

LIPID STORAGE DISEASES

LIPID STORAGE DISEASES

14問 • 2年前

Yves Laure Pimentel · 71問 · 2年前

PROTEINS

PROTEINS

71問 • 2年前

Yves Laure Pimentel · 7問 · 2年前

QUICK FIRE- ELECTRODES

QUICK FIRE- ELECTRODES

7問 • 2年前

Yves Laure Pimentel · 10問 · 2年前

ELECTROLYTES

ELECTROLYTES

10問 • 2年前

Yves Laure Pimentel · 27問 · 2年前

DRUGS

DRUGS

27問 • 2年前

Yves Laure Pimentel · 12問 · 2年前

TOXIC AGENTS:

TOXIC AGENTS:

12問 • 2年前

HEMATOLOGY 1 (HEMATOPOIESIS 1)

HEMATOLOGY 1 (HEMATOPOIESIS 1)

Yves Laure Pimentel · 29問 · 2年前

HEMATOLOGY (HEMATOPOIESIS 2)

HEMATOLOGY (HEMATOPOIESIS 2)

29問 • 2年前

Yves Laure Pimentel · 25問 · 2年前

hema diseases

hema diseases

25問 • 2年前

Yves Laure Pimentel · 43問 · 2年前

AML

AML

43問 • 2年前

Yves Laure Pimentel · 71問 · 2年前

GLOBIN SYNTHESIS

GLOBIN SYNTHESIS

71問 • 2年前

Yves Laure Pimentel · 31問 · 2年前

HEMATOLOGY REFERENCE RANGES

HEMATOLOGY REFERENCE RANGES

31問 • 2年前

Yves Laure Pimentel · 34問 · 2年前

DISORDERS OF PRIMARY HEMOSTASIS

DISORDERS OF PRIMARY HEMOSTASIS

34問 • 2年前

Yves Laure Pimentel · 37問 · 2年前

PLATELET DISORDERS

PLATELET DISORDERS

37問 • 2年前

CHARACTERISTICS OF CLOTTING FACTORS

CHARACTERISTICS OF CLOTTING FACTORS

Yves Laure Pimentel · 12問 · 2年前

4. CLASSIFICATION OF MACROPHAGE

4. CLASSIFICATION OF MACROPHAGE

12問 • 2年前

Yves Laure Pimentel · 39問 · 2年前

3. NATURAL OR INNATE IMMUNITY

3. NATURAL OR INNATE IMMUNITY

39問 • 2年前

Yves Laure Pimentel · 55問 · 2年前

5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

55問 • 2年前

Yves Laure Pimentel · 37問 · 2年前

6. PHAGOCYTOSIS Chemotaxis

6. PHAGOCYTOSIS Chemotaxis

37問 • 2年前

Yves Laure Pimentel · 44問 · 2年前

8. NATURE OF ANTIGEN

8. NATURE OF ANTIGEN

44問 • 2年前

Yves Laure Pimentel · 50問 · 2年前

9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

50問 • 2年前

Yves Laure Pimentel · 69問 · 2年前

1. HISTORY

1. HISTORY

69問 • 2年前

Yves Laure Pimentel · 38問 · 2年前

2. TYPES OF IMMUNITY

2. TYPES OF IMMUNITY

38問 • 2年前

Yves Laure Pimentel · 21問 · 2年前

7. PHAGOCYTOSIS Engulfment and Digestion

7. PHAGOCYTOSIS Engulfment and Digestion

21問 • 2年前

Yves Laure Pimentel · 15問 · 2年前

8. PHAGOCYTOSIS EXOCYTOSIS

8. PHAGOCYTOSIS EXOCYTOSIS

15問 • 2年前

Yves Laure Pimentel · 32問 · 2年前

10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

32問 • 2年前

Yves Laure Pimentel · 30問 · 2年前

11. TRANSPLANTATION IMMUNOLOGY

11. TRANSPLANTATION IMMUNOLOGY

30問 • 2年前

Yves Laure Pimentel · 38問 · 2年前

2. LYMPHOID ORGANS

2. LYMPHOID ORGANS

38問 • 2年前

Yves Laure Pimentel · 48問 · 2年前

3. CLUSTER OF DIFFERENTIATION

3. CLUSTER OF DIFFERENTIATION

48問 • 2年前

Yves Laure Pimentel · 35問 · 2年前

4. T-CELL DIFFERENTIATION

4. T-CELL DIFFERENTIATION

35問 • 2年前

Yves Laure Pimentel · 18問 · 2年前

5. T CELL IMMUNODEFICIENCIES

5. T CELL IMMUNODEFICIENCIES

18問 • 2年前

Yves Laure Pimentel · 44問 · 2年前

6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

44問 • 2年前

Yves Laure Pimentel · 23問 · 2年前

7. B CELL IMMUNODEFICIENCIES

7. B CELL IMMUNODEFICIENCIES

23問 • 2年前

Yves Laure Pimentel · 34問 · 2年前

8. COMBINED T CELL AND B CELL DEFICIENCIES

8. COMBINED T CELL AND B CELL DEFICIENCIES

34問 • 2年前

Yves Laure Pimentel · 12問 · 2年前

9. COMPARISON OF T AND B CELLS

9. COMPARISON OF T AND B CELLS

12問 • 2年前

Yves Laure Pimentel · 16問 · 2年前

10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

16問 • 2年前

Yves Laure Pimentel · 15問 · 2年前

11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

15問 • 2年前

Yves Laure Pimentel · 79問 · 2年前

12. ANTIBODY

12. ANTIBODY

79問 • 2年前

Yves Laure Pimentel · 97問 · 2年前

13. TYPES OF ANTIBODIES

13. TYPES OF ANTIBODIES

97問 • 2年前

Yves Laure Pimentel · 11問 · 2年前

14. MONOCLONAL ANTIBODIES

14. MONOCLONAL ANTIBODIES

11問 • 2年前

Yves Laure Pimentel · 23問 · 2年前

1. INTERLEUKINS

1. INTERLEUKINS

23問 • 2年前

Yves Laure Pimentel · 28問 · 2年前

2. INTERFERONS

2. INTERFERONS

28問 • 2年前

Yves Laure Pimentel · 8問 · 2年前

3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

8問 • 2年前

Yves Laure Pimentel · 19問 · 2年前

4. COMPLEMENT SYSTEM

4. COMPLEMENT SYSTEM

19問 • 2年前

Yves Laure Pimentel · 76問 · 2年前

15. COMPLEMENT SYSTEM

15. COMPLEMENT SYSTEM

76問 • 2年前

Yves Laure Pimentel · 21問 · 2年前

16. SYSTEM CONTROLS/COMPLEMENT REGULATION

16. SYSTEM CONTROLS/COMPLEMENT REGULATION

21問 • 2年前

Yves Laure Pimentel · 29問 · 2年前

17. COMPLEMENT AND DISEASE STATES

17. COMPLEMENT AND DISEASE STATES

29問 • 2年前

Yves Laure Pimentel · 19問 · 2年前

18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

19問 • 2年前

Yves Laure Pimentel · 22問 · 2年前

19. CYTOKINES

19. CYTOKINES

22問 • 2年前

Yves Laure Pimentel · 24問 · 2年前

20. INTERLEUKINS

20. INTERLEUKINS

24問 • 2年前

Yves Laure Pimentel · 21問 · 2年前

21. INTERFERONS, TNF, TGF, CHEMOKINE

21. INTERFERONS, TNF, TGF, CHEMOKINE

21問 • 2年前

Yves Laure Pimentel · 54問 · 2年前

1. SERO

1. SERO

54問 • 2年前

Yves Laure Pimentel · 38問 · 2年前

2. PRECIPITATION

2. PRECIPITATION

38問 • 2年前

Yves Laure Pimentel · 17問 · 2年前

3. PASSIVE IMMUNODIFFUSION

3. PASSIVE IMMUNODIFFUSION

17問 • 2年前

Yves Laure Pimentel · 15問 · 2年前

4. OUCHTERLONY

4. OUCHTERLONY

15問 • 2年前

Yves Laure Pimentel · 9問 · 2年前

5. ELECTROPHORETIC TECHNIQUE

5. ELECTROPHORETIC TECHNIQUE

9問 • 2年前

Yves Laure Pimentel · 11問 · 2年前

6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

11問 • 2年前

Yves Laure Pimentel · 29問 · 2年前

7. IMMUNOFIXATION ELECTROPHORESIS

7. IMMUNOFIXATION ELECTROPHORESIS

29問 • 2年前